GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » Cyclically Adjusted PB Ratio

Tyme Technologies (Tyme Technologies) Cyclically Adjusted PB Ratio : (As of May. 06, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Tyme Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Tyme Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyme Technologies Cyclically Adjusted PB Ratio Chart

Tyme Technologies Annual Data
Trend Nov12 Nov13 Nov14 Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tyme Technologies Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tyme Technologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Tyme Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tyme Technologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyme Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Tyme Technologies's Cyclically Adjusted PB Ratio falls into.



Tyme Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Tyme Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2022 is calculated as:

For example, Tyme Technologies's adjusted Book Value per Share data for the three months ended in Jun. 2022 was:

Adj_Book=Book Value per Share/CPI of Jun. 2022 (Change)*Current CPI (Jun. 2022)
=0.431/125.0168*125.0168
=0.431

Current CPI (Jun. 2022) = 125.0168.

Tyme Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201208 0.000 97.199 0.000
201211 0.000 97.133 0.000
201302 0.000 97.953 0.000
201305 0.000 98.282 0.000
201308 -0.001 98.675 -0.001
201311 -0.001 98.334 -0.001
201402 -0.001 99.057 -0.001
201405 -0.001 100.373 -0.001
201408 -0.002 100.352 -0.002
201411 -0.002 99.635 -0.003
201502 -0.002 99.032 -0.003
201506 0.027 100.684 0.034
201509 0.004 100.392 0.005
201512 0.035 99.792 0.044
201603 0.050 100.470 0.062
201606 0.030 101.688 0.037
201609 0.010 101.861 0.012
201612 0.005 101.863 0.006
201703 0.084 102.862 0.102
201706 0.096 103.349 0.116
201709 0.063 104.136 0.076
201712 0.098 104.011 0.118
201803 0.262 105.290 0.311
201806 0.218 106.317 0.256
201809 0.202 106.507 0.237
201812 0.152 105.998 0.179
201903 0.093 107.251 0.108
201906 0.107 108.070 0.124
201909 0.065 108.329 0.075
201912 0.021 108.420 0.024
202003 0.154 108.902 0.177
202006 0.125 108.767 0.144
202009 0.111 109.815 0.126
202012 0.070 109.897 0.080
202103 0.591 111.754 0.661
202106 0.560 114.631 0.611
202109 0.531 115.734 0.574
202112 0.503 117.630 0.535
202203 0.465 121.301 0.479
202206 0.431 125.017 0.431

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Tyme Technologies  (NAS:TYME) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Tyme Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Tyme Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tyme Technologies (Tyme Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921
Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.
Executives
Michael Demurjian director, 10 percent owner, officer: Chief Operating Officer 157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman director, 10 percent owner, officer: CEO and Chief Science Officer 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl director 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido officer: Chief Financial Officer C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini officer: Corporate Controller 17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry director 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M officer: Acting Chief Medical Officer 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels director 220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman officer: EVP, Product Development 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor officer: President and CFO 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin officer: Chief Operating Officer 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

Tyme Technologies (Tyme Technologies) Headlines

From GuruFocus